Back to Results

Aardvark Therapeutics Inc (AARD)

Featured in High-Beta Momentum

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies that aim to activate innate homeostatic pathways for the treatment of metabolic diseases. The company was incorporated in 2017 and is headquartered in San Diego, California. Its common stock trades on the NASDAQ exchange under the ticker AARD.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-AARD
$5.96
10.8% Upside
Fair
$11.11
106.5% Upside
Bargain
Fair
0.0%
November 12, 2026
1.6x
117.7 M
44.547 M
0.6%
50.3%
6.4
99.3%
Valuation • Fair Value

Aardvark Therapeutics Inc (NASDAQ-AARD) Fair Value by Valuation Model

Review the available estimates for Aardvark Therapeutics Inc (NASDAQ-AARD), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$5.96

Estimated upside of 10.8% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$6.35

Discounted cash flow valuation reference.

Comps Fair Value

$5.67

Comparable-company valuation reference.

Analyst Price Target

$11.11

Analysts imply upside of 106.5%.

How to read these valuation models

Use the 5 available valuation references for Aardvark Therapeutics Inc (NASDAQ-AARD) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Aardvark Therapeutics Inc (NASDAQ-AARD)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-73.913 M

Current operating profitability reference.

EBITDA Forecast

-61.196 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Aardvark Therapeutics Inc (NASDAQ-AARD) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Aardvark Therapeutics Inc (NASDAQ-AARD)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

0

Weak quality score that deserves closer review.

Altman Z-Score

6.4

Relatively strong balance-sheet zone.

FCF / Net Income

99.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Aardvark Therapeutics Inc (NASDAQ-AARD). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Aardvark Therapeutics Inc (NASDAQ-AARD)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 12, 2026

Days to Earnings

55

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Aardvark Therapeutics Inc (NASDAQ-AARD), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Aardvark Therapeutics Inc (NASDAQ-AARD) Stock Forecast & Technical Outlook

Review Aardvark Therapeutics Inc (NASDAQ-AARD) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Aardvark Therapeutics Inc (NASDAQ-AARD) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Aardvark Therapeutics Inc (NASDAQ-AARD) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Aardvark Therapeutics Inc (NASDAQ-AARD) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Aardvark Therapeutics Inc (NASDAQ-AARD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Aardvark Therapeutics Inc (NASDAQ-AARD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Aardvark Therapeutics Inc (NASDAQ-AARD)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Aardvark Therapeutics Inc (NASDAQ-AARD) has a Buy consensus, with 6 buy, 4 hold and 1 sell recommendations in the current data set.

Buy 6
Hold 4
Sell 1
FAQ • Fast Investor Answers

Aardvark Therapeutics Inc (NASDAQ-AARD) Stock FAQ

Data-supported answers about Aardvark Therapeutics Inc (NASDAQ-AARD), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$5.96
Estimated upside 10.8%
Valuation Rating
Undervalued
Estimated upside of 10.8%
Analyst Target
$11.11
Implied upside 106.5%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Aardvark Therapeutics Inc (NASDAQ-AARD) is $5.96. This implies an estimated upside of 10.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 10.8% versus the current market price.

The available analyst price target for Aardvark Therapeutics Inc (NASDAQ-AARD) is $11.11. The analyst target implies estimated upside of 106.5%.

The current financial health read for Aardvark Therapeutics Inc (NASDAQ-AARD) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Aardvark Therapeutics Inc (NASDAQ-AARD) is November 12, 2026.

The latest available data indicates no current dividend yield for Aardvark Therapeutics Inc (NASDAQ-AARD).

The current market capitalization listed for Aardvark Therapeutics Inc is 117.7 M.

The current enterprise value listed for Aardvark Therapeutics Inc is 44.547 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Aardvark Therapeutics Inc is NASDAQ-AARD, and the stock is listed on NASDAQ.

Aardvark Therapeutics Inc (NASDAQ-AARD) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Aardvark Therapeutics Inc is 0.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Aardvark Therapeutics Inc is 50.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.628 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B